Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Avidity Biosciences, Inc. - Common Stock
(NQ:
RNA
)
72.91
-0.01 (-0.01%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Avidity Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tesla, Amazon, Novavax, Lennar Corp, Avidity Biosciences: Why These 5 Stocks Are Drawing Retail Investors' Attention Today
↗
December 14, 2022
Major Wall Street indices closed in the red on Wednesday despite an anticipated 50 basis points hike by the Federal Reserve as Chair Jerome Powell indicated the need for more data before the central...
Via
Benzinga
Expert Ratings for Avidity Biosciences
↗
December 14, 2022
Via
Benzinga
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
↗
December 14, 2022
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.
Via
Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
↗
December 14, 2022
Business wins are shining the spotlight on these two companies.
Via
The Motley Fool
Avidity Biosciences (NASDAQ: RNA) Posts Positive Phase 1/2 MARINA Data on AOC 1001, Announcing the First Successful Delivery of RNA to Muscle
December 14, 2022
Avidity Biosciences, Inc. (NASDAQ: RNA) is engaged as a biopharmaceutical company, which is focused on developing a new class of
Via
Spotlight Growth
Recap: Avidity Biosciences Q2 Earnings
↗
August 09, 2022
Avidity Biosciences (NASDAQ:RNA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Avidity Biosciences
↗
July 20, 2022
Avidity Biosciences (NASDAQ:RNA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
↗
July 20, 2022
Via
Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
↗
December 14, 2022
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Via
Benzinga
How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere
↗
December 14, 2022
The company tested its efforts in myotonic dystrophy 1, a form of muscular dystrophy.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
December 14, 2022
Via
Benzinga
Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial
↗
December 14, 2022
Via
Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
↗
December 14, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
What's Going On With Avidity Biosciences Stock?
↗
December 14, 2022
Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 14, 2022
Via
Benzinga
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
↗
November 21, 2022
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.
Via
Benzinga
Short Interest Sector Focus: Healthcare Sector
↗
October 20, 2022
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...
Via
Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
↗
September 28, 2022
Gainers
Via
Benzinga
Nasdaq Turns Higher; Crude Oil Rises Over 2%
↗
September 27, 2022
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 27, 2022
Gainers
Via
Benzinga
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
↗
September 27, 2022
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
US Stocks Turn Lower; Dow Dips 175 Points
↗
September 27, 2022
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday.
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
↗
September 27, 2022
Gainers
Via
Benzinga
US Stocks Open Higher; Dow Surges 300 Points
↗
September 27, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Tuesday.
Via
Benzinga
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
↗
September 27, 2022
The stock has a high IBD Digital rating, but plummeted on the news.
Via
Investor's Business Daily
FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial
↗
September 27, 2022
The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 27, 2022
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million.
Via
Benzinga
Short Interest Sector Focus: Healthcare Sector
↗
September 26, 2022
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...
Via
Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
↗
September 23, 2022
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.
Via
InvestorPlace
Short Interest Sector Focus: Healthcare Sector
↗
August 30, 2022
As of the close of business on Monday, 8/29, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today